IONIS PHARMACEUTICALS INC

IONS
About the company

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).

Country: United StatesPrice: $29.06Market Cap: $4.8B

Investment snapshot

18%positive consensus
Scored 1d ago

Positive

3

BUY / PASS

Neutral / negative

1 / 12

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Buffett, Lynch and Marks object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2106 (Top 68%)PASSFAILFAILFAILFAILFAILPASSPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-26

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-09

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-09

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 12✗ 3▾

    9 of 12 pass — Buffett, Lynch and Marks object

    LT Debt vs Net Current AssetsLT Debt $1.3B vs NCA $2.2B
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: -29.4x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt$-955.7M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change40.03% -> 37.69%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities5.43
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-22.1x, D/EBITDA=N/A (D&A unavailable)
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio9.8x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-6.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-6.1%, ROC=-16.0%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share9.8x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation Reasonableness
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-6.6%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=9.8x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low100% of trailing low ($29.06)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-11.29%; #4234/6340 (top 66.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.0813; #4852/6449 (top 75.2%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share9.82x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-43.9%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1984; #3796/5247 (top 72.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-12.73%; #3328/4519 (top 73.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-61.34%; #5431/6202 (top 87.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy
    ✗BuffettPositive and growing
    FCF Positive and Growing$-616.3M
    ✗LynchPositive and growing
    Operating Cash Flow$-268.6M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-7.62%, ROA=-10.82%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-6.6%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive9/18 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-12.8%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency10/18 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-616.3M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-12.73%; #3328/4519 (top 73.6%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 173.0% vs Rev: -0.7%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.19 (2008) -> $-2.38 (2025)
    ✗DremanPositive over recent years
    EPS CAGR2.8% CAGR over 10 years
    ✗Dreman> 5% annualized
    Positive Net Income Frequency4/18 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth33.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency2/5 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 98.8% -> 98.3%, operating margin -44.9% -> -40.4%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR5.3%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability6% pass✓ 5✗ 30▾

    15 of 16 flag IONS's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)4/28 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)4/28 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-60.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-40.4% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-138.8%
    ✗Lynch> 15%
    EBIT / Enterprise Value-6.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-6.1%, ROC=-16.0%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-10.82%
    ✗PiotroskiROA > 0
    ROA Change YoY-15.11% -> -10.82% (delta: +4.29%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-7.62%, ROA=-10.82%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY98.4% -> 98.3%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-56.6%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-138.8%
    ✗Dreman> 12%
    Margin of SafetyP/B=9.8x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-83.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency4/18 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-58.8%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-138.8%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-44.9% (2023) -> -40.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 98.8% -> 98.3%, operating margin -44.9% -> -40.4%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-11.29%; #4234/6340 (top 66.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+26.33%; #1634/3702 (top 44.1%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-138.84%; #4748/5226 (top 90.9%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0472; #2511/5884 (top 42.7%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years3/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts19% pass✓ 3✗ 13▾

    Split decision: 12 FAIL · 3 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2106✓PiotroskiPASS (F-Score 4)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1943/2370 (Top 82.0%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag IONS's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio5.43
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-19.3%
    ✗Buffett> 10%
    ROIC - WACC-29.3%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-16.0%
    ✗Greenblatt> 25%
    Current Ratio Change YoY8.47 -> 3.83
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.23x -> 0.27x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities5.43
    ✓Dreman> 1.5
    Return on Invested Capital-113.4%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-17.2%; FY2024: ROIC=-21.0%; FY2025: ROIC=-13.4%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest -13.4%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($4.8B)
Revenue: $943.7M+33.8% YoY
Net Income: $381.4M+16.0% YoY

Financial Snapshot

Operating Margin-40.4%
Return on Equity-78.0%
Debt / Equity3.60
Current Ratio3.83
EPS (Diluted)$-2.38
Shares Retired−3.9% / −13.3% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 3.9% of shares last year, 13.3% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: pre tax income, interest expense, operating cash flow, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-26
FY 2024
Sources
  • 10-K · 2025-02-19
FY 2023
Sources
  • 10-K · 2024-02-21
FY 2022
Sources
  • 10-K · 2024-02-21
FY 2021
Sources
  • 10-K · 2022-02-25
Market Cap$4.8Bcurrent------$13.7Best.$5.1Best.$7.5Best.$5.7Best.$4.5Best.
Revenue$960.1M↓1%$242.7M↑55%$267.9M↓41%$246.1M↑87%$943.7M↑34%$705.1M↓10%$787.6M↑34%$587.4M↓28%$810.5M
Operating Income-$564.9M↓103%-$130.7M↑18%-$102.3M↓173%-$117.4M↑20%-$381.7M↑20%-$475.1M↓34%-$353.7M↑14%-$410.2M↓1259%-$30.2M
Net Income-$546.5M↓113%-$110.0M↑14%-$114.6M↓193%-$92.5M↑37%-$381.4M↑16%-$453.9M↓24%-$366.3M↓36%-$269.7M↓843%-$28.6M
EPS (Diluted)--$-0.66↑18%$-0.69↓199%$-0.56↑40%$-2.38↑22%$-3.04↓19%$-2.56↓35%$-1.90↓850%$-0.20
Gross Margin————98.3%98.4%98.8%↑1%97.6%↓1%98.7%
Operating Margin-58.8%↓105%-53.8%↑47%-38.2%↓223%-47.7%↑57%-40.4%↑40%-67.4%↓50%-44.9%↑36%-69.8%↓1775%-3.7%
ROE-138.8%↓235%———-78.0%↓1%-77.1%↑19%-94.7%↓101%-47.1%↓1171%-3.7%
Total Debt$0↓100%$0↓100%$0↓100%$432.5M$1.8B↑46%$1.2B↓3%$1.2B↑6%$1.2B--
Shareholders' Equity$393.6M↓36%$393.6M↓36%$439.7M↓30%$491.4M↑3%$489.1M↓17%$588.4M↑52%$386.7M↓33%$572.9M↓26%$771.7M
Current Ratio5.43↑95%5.43↑95%7.89↑175%4.10↓58%3.83↓55%8.47↑44%5.90↓17%7.07↓27%9.75
Debt / Equity0.00↓100%0.00↓100%0.00↓100%0.883.60↑76%2.04↓36%3.21↑56%2.05—
Operating Cash Flow-$544.4M↓120%-$179.4M↓37%$565.5M↑274%-$792.8M↓426%-$268.6M↑46%-$500.9M↓63%-$307.5M↓12%-$274.4M↓991%$30.8M
Free Cash Flow-$616.3M↓104%-$192.1M↓41%$549.5M↑295%-$814.6M↓399%-$320.0M↑41%-$546.2M↓65%-$331.3M↓14%-$290.1M↓1639%$18.8M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

IONS vs Peers — Financial Grading

Revenue$943.7MMedian
Net Income$381.4MBottom 25%
ROE-78.0%Bottom 25%
D/E3.60Bottom 25%
Op. Margin-40.4%Bottom 25%
Curr. Ratio3.83Median
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11
Celldex Therapeutics, Inc.CLDX$2.3B$28.83$1.5M$258.8M-49.1%—-18599.8%10.491/90/91/70/3F-Score 22/11